PATIENT INFORMATION

BIZENGRI® (bi zen gree)
(zenocutuzumab-zbco)
injection, for intravenous use

What is the most important information I should know about BIZENGRI?

BIZENGRI may cause serious side effects, including:

- **Infusion-related, allergic and anaphylactic reactions.** BIZENGRI may cause serious infusion-related and allergic reactions that can be life-threatening. Infusion-related reactions are also common during BIZENGRI treatment. Before each BIZENGRI infusion, your healthcare provider will give you medicines to help reduce your chance of getting infusion-related reactions. Your healthcare provider will monitor you for signs and symptoms during your infusion and for at least 1 hour after your first infusion and as needed. Tell your healthcare provider right away if you develop any of the following signs or symptoms during or after your BIZENGRI infusion:
  - chills or shaking
  - nausea, vomiting, or diarrhea
  - fever
  - cough
  - sudden swelling of your face, tongue, throat, or troubled swallowing
  - throat tightness or discomfort
  - itching or rash
  - shortness of breath or wheezing
  - chest discomfort
  - feeling light-headed
  - dizziness
  - back or neck pain
  - feeling of numbness or tingling
- **Lung problems.** BIZENGRI may cause serious lung problems that may be life-threatening. If you develop lung problems, your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you develop any new or worsening symptoms of lung problems, including:
  - trouble breathing
  - shortness of breath
  - cough
  - fever
- **Heart problems that may affect your heart's ability to pump blood.** BIZENGRI may cause serious and life-threatening heart problems that may lead to death. Your healthcare provider will check your heart function before you start treatment with BIZENGRI and as needed during your treatment. Tell your healthcare provider right away if you develop any new or worsening symptoms of heart problems, including:
  - shortness of breath
  - coughing
  - tiredness
  - swelling of your feet, ankles or legs
  - irregular heartbeat
  - sudden weight gain
  - dizziness or feeling light-headed
  - loss of consciousness

Your healthcare provider will check you for these side effects during your treatment with BIZENGRI and may delay your treatment, slow the infusion rate, or completely stop your treatment with BIZENGRI if you develop severe side effects.

- **Harm to your unborn baby.** Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with BIZENGRI.
  Females who are able to become pregnant:
  - Your healthcare provider will do a pregnancy test before you start treatment with BIZENGRI.
  - Use effective birth control (contraception) during treatment and for 2 months after your last dose of BIZENGRI.

See **"What are the possible side effects of BIZENGRI?"** for more information about side effects.

What is BIZENGRI?

BIZENGRI is a prescription medicine used to treat adults who have:

- lung cancer called non-small cell lung cancer (NSCLC):
  - that has a neuregulin 1 (*NRG1*) gene fusion and cannot be removed by surgery or has spread to other parts of the body (advanced unresectable or metastatic), **and**
  - whose disease has worsened on or after prior cancer treatment.
- pancreatic cancer called pancreatic adenocarcinoma:
  - that has a neuregulin 1 (*NRG1*) gene fusion and cannot be removed by surgery or has spread to other parts of the body (advanced unresectable or metastatic), **and**
  - whose disease has worsened on or after prior cancer treatment.

It is not known if BIZENGRI is safe and effective in children.

Before receiving BIZENGRI, tell your healthcare provider about all your medical conditions, including if you:

- have lung or breathing problems other than your lung cancer.
- have or have had any heart problems.
- are breastfeeding or plan to breastfeed. It is not known if BIZENGRI passes into your breast milk. Do not breastfeed during treatment and for 2 months after your last dose of BIZENGRI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements.

How will I receive BIZENGRI?

- BIZENGRI will be given to you by your healthcare provider as an intravenous (IV) infusion into your vein, usually over 4 hours.
- BIZENGRI is usually given 1 time every 2 weeks.
- Your healthcare provider will decide how many treatments you will need.

What are the possible side effects of BIZENGRI?

BIZENGRI may cause serious side effects, including:

- See **"What is the most important information I should know about BIZENGRI?"**

The most common side effects of BIZENGRI include:

- diarrhea
- muscle or bone pain
- tiredness
- nausea
- shortness of breath
- rash
- constipation
- vomiting
- stomach-area (abdominal) pain
- swelling of your breast, face, ankles or legs

The most common severe abnormal blood test results with BIZENGRI include:

- increased blood levels of liver enzymes and bilirubin
- decreased red blood cell counts and platelet counts
- decreased blood level of sodium, magnesium, and phosphate
- increase in the time that it takes your blood to clot

These are not all of the possible side effects of BIZENGRI.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about safe and effective use of BIZENGRI:

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about BIZENGRI that is written for health professionals.

What are the ingredients in BIZENGRI?

Active ingredient: zenocutuzumab-zbco

Inactive ingredients: histidine, L-histidine hydrochloride monohydrate, polysorbate 20, trehalose, and water for injection

Manufactured by: Partner Therapeutics, Inc. Lexington, MA 02421

U.S. License Number 2087

For more information call 1-888-479-5385
AW029-01 -- PPI-013 V2.0

This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: Mar/2025